National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Paliperidone palmitate (Xeplion®) is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate, and a long acting injectable treatment is needed.

Rapid Review

Commenced Completed Outcome
23/03/2011 April 2011 Full Pharmacoeconomic Evaluation not Recommended.